344 related articles for article (PubMed ID: 6230083)
21. Experiences on the efficacy and safety of nalidixic acid, oxolinic acid, cinoxacin and norfloxacin in the treatment of urinary tract infections (UTI).
Sabbour MS; El Bokl MA; Osman LM
Infection; 1984; 12(6):377-80. PubMed ID: 6240470
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.
Gadebusch HH; Shungu DL; Weinberg E; Chung SK
Infection; 1982 Jan; 10(1):41-4. PubMed ID: 6461606
[TBL] [Abstract][Full Text] [Related]
23. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
King A; Shannon K; Phillips I
J Antimicrob Chemother; 1984 Apr; 13(4):325-31. PubMed ID: 6233249
[TBL] [Abstract][Full Text] [Related]
24. Antibacterial activity of miloxacin.
Izawa A; Kisaki Y; Irie K; Eda Y; Nakagome T; Komatsu T
Antimicrob Agents Chemother; 1980 Jul; 18(1):37-40. PubMed ID: 7416749
[TBL] [Abstract][Full Text] [Related]
25. Cross resistance of quinolone derivatives in gram-negative bacteria.
Barba D; Pennucci C; Esposito S; Galante D
Chemioterapia; 1985 Apr; 4(2):192-6. PubMed ID: 3159488
[TBL] [Abstract][Full Text] [Related]
26. Research on antibacterial and antifungal agents. III. Synthesis of 1-ethyl-1,4-dihydro-4-oxo-7-(1-pyrryl)quinoline-3-carboxylic acid and of some 6-derivatives.
Artico M; Corelli F; Massa S; Stefancich G; Panico S; Simonetti N
Farmaco Sci; 1984 Nov; 39(11):910-24. PubMed ID: 6440810
[TBL] [Abstract][Full Text] [Related]
27. Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar.
Tenney JH; Maack RW; Chippendale GR
Antimicrob Agents Chemother; 1983 Jan; 23(1):188-9. PubMed ID: 6219620
[TBL] [Abstract][Full Text] [Related]
28. Activity of flumequine against Escherichia coli: in vitro comparison with nalidixic and oxolinic acids.
Greenwood D
Antimicrob Agents Chemother; 1978 Mar; 13(3):479-83. PubMed ID: 400825
[TBL] [Abstract][Full Text] [Related]
29. In vitro sensitivity pattern of gram negative pathogens to nalidixic acid.
Chitkara YK
Indian J Pathol Bacteriol; 1969 Oct; 12(4):162-8. PubMed ID: 4990210
[No Abstract] [Full Text] [Related]
30. Norfloxacin: in vitro activity compared with that of seven other antibacterial agents against urinary tract pathogens.
Digranes A; Dibb WL; Ostervold B
Acta Pathol Microbiol Immunol Scand B; 1984 Apr; 92(2):101-6. PubMed ID: 6233841
[TBL] [Abstract][Full Text] [Related]
31. [Antibacterial activity of enoxacin in vitro and in urine].
Soussy CJ; Deforges L; Duval J
Pathol Biol (Paris); 1987 May; 35(5):475-81. PubMed ID: 3302849
[TBL] [Abstract][Full Text] [Related]
32. In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.
Heessen FW; Muytjens HL
Antimicrob Agents Chemother; 1984 Jan; 25(1):123-4. PubMed ID: 6230988
[TBL] [Abstract][Full Text] [Related]
33. Antibacterial activity of the metabolites of ciprofloxacin and its significance in the bioassay.
Zeiler HJ; Petersen U; Gau W; Ploschke HJ
Arzneimittelforschung; 1987 Feb; 37(2):131-4. PubMed ID: 3555512
[TBL] [Abstract][Full Text] [Related]
34. [Influence of technical factors in the determination of minimal inhibitory concentration by microdilution].
Forey F; Coulet M; Brun Y; Fleurette J
Pathol Biol (Paris); 1985 May; 33(5):341-9. PubMed ID: 3162138
[TBL] [Abstract][Full Text] [Related]
35. [Multicenter study of ofloxacin activity on bacteria isolated from a hospital environment].
Soussy CJ; Le Van Thoi J; Duval J; Morel C; Malbruny B; Acar JF; Kitzis MD; Mounier M; Denis F; Courvalin P
Pathol Biol (Paris); 1986 May; 34(5):390-8. PubMed ID: 3534711
[TBL] [Abstract][Full Text] [Related]
36. Antibacterial activity of six beta-lactams and six quinolones against urinary gram negative bacteria.
Galante D; Esposito S; Barba D
Boll Ist Sieroter Milan; 1986; 65(5):361-7. PubMed ID: 3828090
[TBL] [Abstract][Full Text] [Related]
37. In vitro antibacterial activity of norfloxacin (MK-0366).
King A; Warren C; Shannon K; Phillips I
Antimicrob Agents Chemother; 1982 Apr; 21(4):604-7. PubMed ID: 6211139
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility of Bordetella pertussis to doxycycline, cinoxacin, nalidixic acid, norfloxacin, imipenem, mecillinam and rifampicin.
Zackrisson G; Brorson JE; Björnegård B; Trollfors B
J Antimicrob Chemother; 1985 May; 15(5):629-32. PubMed ID: 2861190
[TBL] [Abstract][Full Text] [Related]
39. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
Guimaraes MA; Noone P
J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
[TBL] [Abstract][Full Text] [Related]
40. [In vitro antibacterial activity of ciprofloxacin against uropathogenic organisms].
Allocati N; Catamo G; Cellini L
Boll Soc Ital Biol Sper; 1984 Oct; 60(10):1927-33. PubMed ID: 6440583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
